WHAT IS CLAIMED IS:

1. A method of combination therapy for treatment of a subject diagnosed as having Fabry disease comprising administering a therapeutically effective amount of a combination therapy selected from two or more of an enzyme replacement therapy, gene therapy, and a small molecule therapy.

2. The method according to claim 1 wherein the combination therapy comprises alternating between administration of an enzyme replacement therapy and a small molecule therapy.

3. The method according to claim 1 wherein the combination therapy comprises simultaneously administering an enzyme replacement therapy and a small molecule therapy.

4. The method according to claim 1 wherein the combination therapy comprises gene therapy and a therapy selected from the group consisting of enzyme replacement therapy and small molecule therapy.

5. The method according to claim 1 wherein the combination therapy produces a diminution in globotriaosylceramide.

6. The method according to claim 1 wherein the enzyme replacement therapy provides an effective amount of α-galactosidase A.

7. The method according to claim 1 wherein the small molecule therapy comprises administering to the subject an effective amount of deoxynojirimycin or a deoxynojirimycin derivative.

8. The method according to claim 7, wherein the deoxynojirimycin derivative is *N*-butyldeoxynojirimycin (*N*B-DNJ) or *N*-(5-adamantane-1-yl-methoxy)pentyl)-deoxynojirimycin (AMP-DNJ).

9. The method according to claim 1, wherein the small molecule therapy comprises administering to the subject an effective amount of a D-*threo*-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol (P4) derivative.

10. The method according to claim 9, wherein the P4 derivative is D-*threo*-1-(3',4'-ethylenedioxy)phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol (D-t-et-P4).

11. The method according to 1, wherein Fabry disease has at least one central nervous system manifestation and the small molecule therapy comprises AMP-DNJ.